Islamabad: Polycystic Ovary Syndrome (PCOS), one of the world’s most common yet misunderstood hormonal disorders affecting women, has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a landmark international consensus published in The Lancet in May 2026.
Experts say the change could improve diagnosis, treatment and awareness for more than 170 million women worldwide, including millions in Pakistan, by better reflecting the condition’s underlying hormonal, metabolic and reproductive abnormalities.
The name change follows a 14 year international effort involving leading researchers, clinicians, patient groups and professional organizations from around the world, who concluded that the term PCOS was scientifically inaccurate, misleading and contributed to delayed diagnosis, fragmented care and stigma.
According to the Lancet paper, PMOS affects around one in every eight women globally but remains substantially underdiagnosed and poorly understood. Researchers noted that the previous name focused narrowly on ovarian cysts, even though many women with the condition do not have cysts and the disorder involves complex hormonal, metabolic and reproductive abnormalities affecting multiple body systems.
The global consensus process included surveys and consultations involving more than 14,000 women living with the condition and healthcare professionals from different regions of the world. Participants overwhelmingly supported replacing the old terminology with a scientifically accurate name that better reflects the nature of the disorder.
Experts said the term “polycystic” created confusion because the structures seen in affected ovaries are not true cysts but immature follicles. The terminology also led many people to view the condition solely as a gynecological disorder, despite growing evidence that insulin resistance, metabolic dysfunction and endocrine disturbances are central features of the syndrome and contribute to increased long term risks of diabetes and cardiovascular disease.
Professor Helena Teede of Monash University, who led the international initiative, said the previous name reduced a complex lifelong endocrine disorder to a misunderstanding about ovarian cysts and contributed to inadequate care and delayed diagnosis for many women.
Researchers said the new name was selected because it better captures the disorder’s endocrine, metabolic and ovarian components while avoiding inaccurate descriptions and reducing confusion and stigma.
Under the new terminology, the word “polyendocrine” reflects the multiple hormonal pathways involved in the disorder, “metabolic” highlights insulin resistance and associated metabolic abnormalities, while “ovarian” recognizes its impact on ovulation, fertility and reproductive health.
Medical experts say PMOS can present with a wide range of symptoms, including irregular menstrual cycles, infertility, weight gain, acne, excessive facial or body hair growth, hair thinning, mood disturbances and metabolic complications. Women with the condition also face increased risks of type 2 diabetes, cardiovascular disease, pregnancy complications and mental health disorders.
The change is particularly relevant for countries like Pakistan, where awareness about the condition remains limited and many women remain undiagnosed for years. Endocrinologists and gynecologists in Pakistan have long warned that rising obesity, sedentary lifestyles and metabolic disorders are contributing to an increasing burden of the condition among young women and adolescent girls.
Researchers hope the new name will encourage healthcare systems to move beyond a narrow reproductive focus and adopt a broader approach that addresses hormonal, metabolic and psychological aspects of the disorder. They also expect the terminology change to improve research funding, public awareness and early detection efforts.
The Lancet authors noted that implementation of the new terminology will occur gradually over a three year transition period, with PMOS expected to be fully incorporated into future international clinical guidelines by 2028.
Health organizations and professional societies in several countries have already begun preparations to adopt the new terminology and educate healthcare professionals and patients about the change.
The consensus paper described the renaming process as one of the largest and most comprehensive disease naming initiatives ever undertaken, arguing that accurate terminology is essential for improving recognition, reducing stigma and ensuring that women receive timely and appropriate care for a condition that has remained neglected for decades despite affecting millions worldwide.
Ends